English

Repare Therapeutics Inc.

EDGAR

RPTX Current report (8-K) · filed 2026-01-28

30 filing records in this dataset, filed from 2020-05-29 to 2026-01-28. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 72.8 million USD 2025-09-30 Source
Exact value

72825000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 43 million shares 2025-09-30 Source
Exact value

42985755 shares

Reported share-count change

1.12% · 475 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

42510708 shares · 2024-09-30· Source
42985755 shares · 2025-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-72.2 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Net income: -84689000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -56018000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -30043000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -16744000 USD · 2025-04-01 – 2025-06-30 Source
Net income: 3258000 USD · 2025-07-01 – 2025-09-30 Source

Operating cash flow

-70.1 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -76445000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -49121000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -29133000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -45475000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -29133000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -42824000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -45475000 USD · 2025-01-01 – 2025-06-30 Source

Capital expenditure

0 USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 0 USD · 2024-01-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-01-28.

Financial data available through: 2024-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 6 of 11 periods available· newest 2024-12-31
Net income: 4 of 11 periods available· newest 2024-12-31
Operating cash flow: 6 of 11 periods available· newest 2024-12-31
Capital expenditure: 6 of 11 periods available· newest 2024-12-31
Total assets: 6 of 11 periods available· newest 2024-12-31
Total liabilities: 6 of 11 periods available· newest 2024-12-31
Current assets: 6 of 11 periods available· newest 2024-12-31
Current liabilities: 6 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 9.11 million

Prior period

−USD 93.8 million

2023-01-01 – 2023-12-31
Current period

−USD 84.69 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-84689000 − -93796000 = 9107000 USD

-93796000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-84689000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Year-over-year change in Net income: 9107000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -84689000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#3240512 Filing: 000095017025030405 Input fundies:NetIncome: -93796000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#3242277 Filing: 000095017025030405
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 50.71 million

Prior period

−USD 127.16 million

2023-01-01 – 2023-12-31
Current period

−USD 76.45 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-76445000 − -127158000 = 50713000 USD

-127158000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-76445000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Year-over-year change in Operating cash flow: 50713000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -76445000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1944511 Filing: 000095017025030405 Input fundies:OperatingCashFlow: -127158000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1946315 Filing: 000095017025030405
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 1.94 million

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 1938000 = -1938000 USD

1938000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Year-over-year change in Capital expenditure: -1938000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1950694 Filing: 000095017025030405 Input fundies:CapitalExpenditure: 1938000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1952338 Filing: 000095017025030405
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	Unavailable Not reported for this period.	−USD 18.43 million Exact value Exact value: -18429000 USD 2019-01-01 – 2019-12-31: -18429000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2019-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: -18429000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2585259 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.	USD 1.3 million Exact value Exact value: 1304000 USD 2019-01-01 – 2019-12-31: 1304000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2019-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 1304000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1304000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2595473 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.	−USD 19.73 million Calculation and evidence -18429000 − 1304000 USD Exact free cash flow: -19733000 USD 2019-01-01 – 2019-12-31: -18429000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1304000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2019-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -19733000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2585259 Filing: 000095017022002560 Input fundies:CapitalExpenditure: 1304000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2595473 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−USD 6.08 million Exact value Exact value: -6084000 USD 2020-01-01 – 2020-12-31: -6084000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2020-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: -6084000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2583064 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.	USD 2.24 million Exact value Exact value: 2237000 USD 2020-01-01 – 2020-12-31: 2237000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2020-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 2237000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2237000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2593464 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.	−USD 8.32 million Calculation and evidence -6084000 − 2237000 USD Exact free cash flow: -8321000 USD 2020-01-01 – 2020-12-31: -6084000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2237000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2020-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -8321000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6084000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2583064 Filing: 000095017022002560 Input fundies:CapitalExpenditure: 2237000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017022002560/rptx-20211231.htm#2593464 Filing: 000095017022002560 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 106.91 million Exact value Exact value: -106908000 USD 2021-01-01 – 2021-12-31: -106908000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Repare Therapeutics Inc. · 2021-12-31 Repare Therapeutics Inc. (edgar:1808158) Net Income: -106908000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -106908000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017023005113/rptx-20221231.htm#3728403 Filing: 000095017023005113 The citation records this snapshot. The page link may show a newer release later.	−USD 85.8 million Exact value Exact value: -85796000 USD 2021-01-01 – 2021-12-31: -85796000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2021-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: -85796000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -85796000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017023005113/rptx-20221231.htm#2382175 Filing: 000095017023005113 The citation records this snapshot. The page link may show a newer release later.	USD 1.69 million Exact value Exact value: 1690000 USD 2021-01-01 – 2021-12-31: 1690000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2021-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 1690000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1690000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017023005113/rptx-20221231.htm#2390080 Filing: 000095017023005113 The citation records this snapshot. The page link may show a newer release later.	−USD 87.49 million Calculation and evidence -85796000 − 1690000 USD Exact free cash flow: -87486000 USD 2021-01-01 – 2021-12-31: -85796000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1690000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2021-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -87486000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -85796000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017023005113/rptx-20221231.htm#2382175 Filing: 000095017023005113 Input fundies:CapitalExpenditure: 1690000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017023005113/rptx-20221231.htm#2390080 Filing: 000095017023005113 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 29.05 million Exact value Exact value: -29047000 USD 2022-01-01 – 2022-12-31: -29047000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Repare Therapeutics Inc. · 2022-12-31 Repare Therapeutics Inc. (edgar:1808158) Net Income: -29047000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29047000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017024021651/rptx-20231231.htm#3005366 Filing: 000095017024021651 The citation records this snapshot. The page link may show a newer release later.	USD 322,000 Exact value Exact value: 322000 USD 2022-01-01 – 2022-12-31: 322000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2022-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: 322000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 322000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017024021651/rptx-20231231.htm#1970617 Filing: 000095017024021651 The citation records this snapshot. The page link may show a newer release later.	USD 602,000 Exact value Exact value: 602000 USD 2022-01-01 – 2022-12-31: 602000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2022-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 602000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 602000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017024021651/rptx-20231231.htm#1975476 Filing: 000095017024021651 The citation records this snapshot. The page link may show a newer release later.	−USD 280,000 Calculation and evidence 322000 − 602000 USD Exact free cash flow: -280000 USD 2022-01-01 – 2022-12-31: 322000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 602000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2022-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -280000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 322000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017024021651/rptx-20231231.htm#1970617 Filing: 000095017024021651 Input fundies:CapitalExpenditure: 602000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017024021651/rptx-20231231.htm#1975476 Filing: 000095017024021651 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 93.8 million Exact value Exact value: -93796000 USD 2023-01-01 – 2023-12-31: -93796000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Repare Therapeutics Inc. · 2023-12-31 Repare Therapeutics Inc. (edgar:1808158) Net Income: -93796000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -93796000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#3242277 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	−USD 127.16 million Exact value Exact value: -127158000 USD 2023-01-01 – 2023-12-31: -127158000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2023-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: -127158000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -127158000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1946315 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	USD 1.94 million Exact value Exact value: 1938000 USD 2023-01-01 – 2023-12-31: 1938000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2023-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 1938000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1938000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1952338 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	−USD 129.1 million Calculation and evidence -127158000 − 1938000 USD Exact free cash flow: -129096000 USD 2023-01-01 – 2023-12-31: -127158000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1938000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2023-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -129096000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -127158000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1946315 Filing: 000095017025030405 Input fundies:CapitalExpenditure: 1938000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1952338 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 84.69 million Exact value Exact value: -84689000 USD 2024-01-01 – 2024-12-31: -84689000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Net Income: -84689000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -84689000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#3240512 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	−USD 76.45 million Exact value Exact value: -76445000 USD 2024-01-01 – 2024-12-31: -76445000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Operating Cash Flow: -76445000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76445000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1944511 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1950694 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.	−USD 76.45 million Calculation and evidence -76445000 − 0 USD Exact free cash flow: -76445000 USD 2024-01-01 – 2024-12-31: -76445000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Repare Therapeutics Inc. · 2024-12-31 Repare Therapeutics Inc. (edgar:1808158) Free cash flow: -76445000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-04T20:27:44Z Snapshot: 7f5ade51f377f1d9d2c5db297f3be11f363c5a8b3c180c6617587c3403851262 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1808158?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76445000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1944511 Filing: 000095017025030405 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1808158/000095017025030405/rptx-20241231.htm#1950694 Filing: 000095017025030405 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,308 latest values · 1,308 originally reported values

Dataset published 2026-11-04. Source filing dates and reporting periods are shown separately.

Identifiers: 0001808158, 1808158, RPTX, edgar:1808158

Also known as Repare Therapeutics Inc.

Repare Therapeutics Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation